NCT03993379Phase 2Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Study sponsor: CytomX Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-05-21Actual
Enrollment · participants3Actual
Source updated2025-12-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.